Key takeaways
- CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog designed to be long-acting, prompting the pituitary to release its own growth hormone rather than supplying GH directly.
- Early human research (a 2006 randomized trial) found sustained increases in growth hormone and IGF-1, with effects lasting well beyond a single day thanks to a drug-affinity-complex design that extends its half-life to roughly a week.
- The human evidence base is small and early, drawn mainly from a few short studies in healthy adults plus supporting animal work, rather than the large long-term trials that back established medicines.
- Because it acts on the GH/IGF-1 axis, CJC-1295 is best considered under qualified medical evaluation and oversight, with route and frequency treated as clinical decisions.
What is CJC-1295?
CJC-1295 is a synthetic peptide that mimics growth-hormone-releasing hormone, or GHRH, the natural signal your body uses to tell the pituitary gland to release growth hormone. Rather than introducing growth hormone from the outside, it is designed to nudge your own pituitary to do the work it already does.
What sets CJC-1295 apart is how long it stays active. It is built with a drug-affinity-complex technology that lets the molecule bind to proteins in the blood, dramatically extending its half-life compared with natural GHRH, which breaks down within minutes. In the published human study the estimated half-life was roughly 6 to 8 days, so a single dose can influence hormone levels over days rather than minutes.
How it works
The mechanism is best described as a secretagogue, something that prompts secretion of another substance. CJC-1295 binds to GHRH receptors on the pituitary and signals it to release growth hormone in a pattern closer to the body's own pulsatile rhythm. That growth hormone, in turn, drives the liver and other tissues to produce insulin-like growth factor 1 (IGF-1), the downstream messenger responsible for many of growth hormone's effects.
A 2009 mechanistic paper described exactly this activation of the GH/IGF-1 axis in healthy adults, tracking measurable changes in serum protein markers after dosing. The appeal in research terms is that because the pituitary is doing the releasing, the body's own feedback loops stay part of the picture, in contrast to administering growth hormone directly.
The human and animal evidence
The most cited human evidence is a 2006 randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism. In healthy adults, CJC-1295 produced prolonged increases in both growth hormone and IGF-1, confirming that the long-acting design translated into measurable, sustained hormonal effects rather than a brief spike.
Supporting work in the same period, published in the American Journal of Physiology, used a GHRH-knockout mouse model to show that once-daily CJC-1295 could normalize growth, and it characterized the long half-life made possible by the drug-affinity-complex approach.
The compound has also been studied in a clinical population. A randomized, placebo-controlled Phase 2 trial registered on ClinicalTrials.gov tested CJC-1295 over 12 weeks in people with HIV-associated visceral obesity, a condition tied to altered growth hormone signaling. That trial was terminated rather than completed, so it adds to the picture of where CJC-1295 has been investigated without contributing finished efficacy results.
This is a small and early body of evidence. The human trial in healthy adults shows that CJC-1295 reliably raises GH and IGF-1, a real and reproducible pharmacological finding. What the published research does not yet do is establish long-term safety, define clinical outcomes, or demonstrate benefit for a specific condition. Much of the supporting data is preclinical or animal-based, and the larger, long-duration human trials that would settle questions of therapeutic value have not been done.
What it is being explored for
Interest in CJC-1295 centers on the GH/IGF-1 axis and its broad role in body composition, recovery, and tissue maintenance. Because its documented effect is a sustained rise in growth hormone and IGF-1, it is studied as a way to support that axis through the body's own pituitary signaling rather than external hormone replacement.
With the evidence still early, the practical question is less what CJC-1295 promises and more what a qualified physician makes of a person's individual hormonal picture, goals, and risks. Route and frequency are clinical decisions, and the GH/IGF-1 axis is sensitive enough that any use belongs under medical evaluation and oversight rather than self-treatment.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. CJC-1295 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.